#200 Harms of Medical Cannabinoids: Up in Smoke!

CLINICAL QUESTION

QUESTION CLINIQUE

What are the harms associated with medical cannabinoid therapy?

BOTTOM LINE

RÉSULTAT FINAL

Compared to placebo, medical cannabinoids cause multiple different adverse events in patients, from visual disturbance or hypotension (1 in 3-10) to hallucination or paranoia (1 in 20). Stopping due to adverse effects occurs in 1 in every 8-20 patients. Regardless of the type of medical cannabinoid used, adverse events are common and likely underestimated. Given the extensive harms, potential benefits must be impressive to warrant a trial of therapy.

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

EVIDENCE

DONNÉES PROBANTES

Eleven systematic reviews with meta-analyses of harm (in general or in treatment of pain/spasticity/nausea and vomiting). Statistically significant unless otherwise noted.

Total adverse events: Four meta-analyses with 3-29 Randomized Controlled Trials (RCTs), 666-3,714 patients.^1-5
- Range^1-3 from relative risk 1.18 to odds ratio (OR) 3.03.
- Percent of patients: 4,5 79-92% cannabinoid versus 56-78% placebo.
  - Number Needed to Harm (NNH)=5-8.
Serious adverse events: Three meta-analyses with 11-34 RCTs, 1,568-3,248 patients.^1,2,6
- Two non-statistically significant.^1,2
- Other OR 1.41 (1.04-1.92), absolute numbers not provided.⁶

Stopped due to adverse events: Seven meta-analyses (2-24 RCTs), 276-2,755 patients.^2,5-10
- Range from^2,7,8 OR 2.94 to Risk Ratio 6.85.
- Actual events:^5-9 7-14% cannabinoid versus 1-5% placebo, NNH=8-22.
- One of the seven meta-analyses was not statistically significant.¹⁰

Specific adverse events versus placebo:
- Predictable effects: Sedation⁸NNH=5, feeling high^7,8 NNH=2-4, euphoria^7,8 NNH=9.
- Common: Visual blurring/hallucination¹¹ NNH=3, dizziness2,5,8,11 NNH=5, speech disorders11 NNH=5, ataxia/muscle twitching11 NNH=6, disconnected thought11 NNH=7, dysphoria8 NNH=8, hypotension8 NNH=8, impaired memory11 NNH=12, disorientation11 NNH=15.
  - Nausea (OR 2.1) and vomiting (OR 1.7) increased, NNH unavailable.²
- Other: Hallucination⁸ NNH=17, paranoia⁸ NNH=20.
- Versus other agents like prochlorperazine, cannabinoids also increased adverse events:⁷ Example sedation (NNH=7) and dizziness (NNH=3).
Adverse events rates varied little between different cannabinoid products (example nabiximol, nabilone, dronabinol, inhaled marijuana, etc.):² NNH=4-7.

Context:  

See Tools for Practice #199 and #201 for potential benefits.
Many studies enrolled patients with a history of medical or recreational cannabinoid use.^11,12 Regular users will:
- Be more tolerant of cannabinoids and less likely to report adverse events.
- Recognize if randomized to cannabinoids or placebo (up to 89% of the time).¹²